Proto Labs Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Proto Labs heeft een totaal eigen vermogen van $680.0M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $753.8M en $73.8M. De EBIT Proto Labs is $29.8M waardoor de rentedekking -13.6 is. Het heeft contanten en kortetermijnbeleggingen van $100.5M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | -13.6x |
| Contant | US$100.51m |
| Aandelen | US$679.99m |
| Totaal verplichtingen | US$73.79m |
| Totaal activa | US$753.79m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Proto Labs' (NYSE:PRLB) Performance Is Even Better Than Its Earnings Suggest
Nov 14
Proto Labs, Inc.'s (NYSE:PRLB) 36% Jump Shows Its Popularity With Investors
Nov 02Here's What's Concerning About Proto Labs' (NYSE:PRLB) Returns On Capital
Sep 08Proto Labs: Defensive Strategy Not Paying Off Yet
Aug 13Calculating The Intrinsic Value Of Proto Labs, Inc. (NYSE:PRLB)
Jul 18Proto Labs: Interesting Crossroads
May 28Proto Labs' (NYSE:PRLB) Solid Earnings Are Supported By Other Strong Factors
May 11Proto Labs, Inc.'s (NYSE:PRLB) Price In Tune With Revenues
Apr 13Proto Labs: Cash Flows Are Supporting The Stock
Mar 04Proto Labs: Excellent Business Feats Yet To Financially Materialize
Feb 16Proto Labs (NYSE:PRLB) May Have Issues Allocating Its Capital
Jan 03Proto Labs: Overlooked Digital Manufacturing Opportunity
Dec 04Proto Labs Remains Profitable Despite So Much Pessimism
Sep 25Proto Labs: The Rally Appears Overdone
Jul 14Be Wary Of Proto Labs (NYSE:PRLB) And Its Returns On Capital
Jul 13Is There An Opportunity With Proto Labs, Inc.'s (NYSE:PRLB) 41% Undervaluation?
May 06Proto Labs (NYSE:PRLB) Might Be Having Difficulty Using Its Capital Effectively
Apr 08Proto Labs Non-GAAP EPS of $0.26 beats by $0.05, revenue of $115.6M beats by $5.47M
Feb 10Proto Labs: Transitioning From A Fast Grower To A Slow Grower
Jan 20Some Investors May Be Worried About Proto Labs' (NYSE:PRLB) Returns On Capital
Dec 21Proto Labs Q3 2022 Earnings Preview
Nov 03Proto Labs: Improvement Of The Digital Model And Undervalued
Oct 27Is It Too Late To Consider Buying Proto Labs, Inc. (NYSE:PRLB)?
Sep 12Protolabs names new technology chief
Sep 08Some Investors May Be Worried About Proto Labs' (NYSE:PRLB) Returns On Capital
Aug 05Proto Labs Q2 2022 Earnings Preview
Aug 04Proto Labs: Not A Great Prospect Until Profitability Issues Clear Up
Jul 07Is Proto Labs, Inc. (NYSE:PRLB) Potentially Undervalued?
May 24Proto Labs (NYSE:PRLB) Could Be Struggling To Allocate Capital
Mar 30The Prognosis For Proto Labs
Feb 22Returns On Capital At Proto Labs (NYSE:PRLB) Paint A Concerning Picture
Nov 28Is There Now An Opportunity In Proto Labs, Inc. (NYSE:PRLB)?
Nov 10Proto Labs: A Play On Additive Manufacturing
Nov 04Investors Could Be Concerned With Proto Labs' (NYSE:PRLB) Returns On Capital
Aug 29Some Investors May Be Willing To Look Past Proto Labs' (NYSE:PRLB) Soft Earnings
Aug 14Estimating The Fair Value Of Proto Labs, Inc. (NYSE:PRLB)
Aug 04Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $193.1M ) PRLB } overtreffen de korte termijn passiva ( $53.8M ).
Langlopende schulden: De kortetermijnactiva PRLB ( $193.1M ) overtreffen de langetermijnschulden ( $20.0M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: PRLB is schuldenvrij.
Schuld verminderen: PRLB had 5 jaar geleden geen schulden.
Schuldendekking: PRLB heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: PRLB heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.